ENTX
Entera Bio LtdNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$60.98M
P/E Ratio
—
EPS
$-0.25
Beta
1.54
52W High
$3.22
52W Low
$0.91
50-Day MA
$1.29
200-Day MA
$1.87
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
—
About Entera Bio Ltd
Entera Bio Ltd., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of orally administered large molecule therapies for unmet medical needs. The company is headquartered in Jerusalem, Israel.
Fundamentals
| Revenue (TTM) | 42,000 |
| Gross Profit (TTM) | 0 |
| EBITDA | $-11.50M |
| Operating Margin | -27450.00% |
| Return on Equity | -108.00% |
| Return on Assets | -56.80% |
| Revenue/Share (TTM) | $0.00 |
| Book Value | $0.28 |
| Price-to-Book | 4.78 |
| Price-to-Sales (TTM) | 1452.00 |
| EV/Revenue | 1333.32 |
| EV/EBITDA | -1.52 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -100.00% |
| Shares Outstanding | $54.45M |
| Float | $32.09M |
| % Insiders | 20.81% |
| % Institutions | 17.13% |
Historical Volatility
HV 10-Day
107.27%
HV 20-Day
122.65%
HV 30-Day
111.61%
HV 60-Day
110.20%
HV Rank
87.7%
Volatility is currently contracting
Analyst Ratings
Consensus ($10.00 target)
1
BuyData last updated: 4/14/2026